Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Renalytix's profit margin for the twelve months ending Sep 30, 2024 was -1191.8%. For fiscal 2024 it was -1461.6%, against -1340.2% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -1461.6% | −121.4 |
| FY2023 | Jun 30, 2023 | -1340.2% | +184.2 |
| FY2022 | Jun 30, 2022 | -1524.4% | +845.5 |
| FY2021 | Jun 30, 2021 | -2370.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -905.7% | +1306.5 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -1207.2% | +936.5 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -1447.3% | +224.8 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -1196.8% | −320.6 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -2212.2% | −978.7 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -2143.6% | −1523.5 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -1672.1% | +137.6 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -876.2% | +937.1 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -1233.5% | +863.1 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -620.1% | +1460.4 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -1809.7% | −392.0 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -1813.3% | +468.2 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -2096.7% | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -2080.5% | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -1417.8% | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -2281.5% | – |
See a number that looks wrong?